Skip to main navigation Skip to search Skip to main content

P245 Real-world elexacaftor/tezacaftor/ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot cystic fibrosis cohort

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of Cystic Fibrosis
DOIs
Publication statusPublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Medicine
  • Sputum
  • Cystic fibrosis
  • Ivacaftor
  • Prospective cohort study
  • Internal medicine
  • Tuberculosis
  • Pathology
  • Cystic fibrosis transmembrane conductance regulator

Cite this